benefit
(statisticaly significant)
benefit (nominaly significant, not statitically demonstrated) NS not significant harm statitically significant NS harm not significant low certainty due to bias
 
pCR

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

versus trastuzumab plus endocrine therapy
trastuzumab emtasine plus endocrine therapy vs. trastuzumab plus endocrine therapy 1 +297%